Correction: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Correction: J Exp Clin Cancer Res 37, 11 (2018)

https://doi.org/10.1186/s13046-018-0671-0

Following publication of the original article [1], the authors have been alerted to an error in Fig. 3A that shows a duplication of a histological image in two panels in the figure. This image duplication error in Fig. 3A was missed by all the authors and reviewers of the paper.

Incorrect Fig. 3

Fig. 3

ONC201 does not impact VEGF expression in xenografts or HUVEC sprouting. a VEGF-A expression as detected by immunohistochemistry in HT29 and HCT116 CRC xenografts. b HUVEC representative images of sprouting from HUVECs grown on Matrigel. c Quantitation of HUVEC sprouting and branching after 12 h of drug treatment. In vivo: n = 5 ONC201 treatment dose was 50 mg/kg weekly. HUVECS N = 4, ONC201 treatment dose 5 μM, bevacizumab dose 5 mg/ml

Correct Fig. 3

Fig. 3

ONC201 does not impact VEGF expression in xenografts or HUVEC sprouting. a VEGF-A expression as detected by immunohistochemistry in HT29 and HCT116 CRC xenografts. b HUVEC representative images of sprouting from HUVECs grown on Matrigel. c Quantitation of HUVEC sprouting and branching after 12 h of drug treatment. In vivo: n = 5 ONC201 treatment dose was 50 mg/kg weekly. HUVECS N = 4, ONC201 treatment dose 5 μM, bevacizumab dose 5 mg/ml